PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This program is supported by grants from AbbVie Inc. and Ironwood Pharmaceuticals, Inc, and Salix Pharmaceuticals.

PROGRAM OVERVIEW

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a significant negative impact on patient quality of life that is commonly managed in primary care. Despite its high prevalence, IBS remains underdiagnosed and undertreated, with affected individuals often experiencing diagnostic delays, inadequate symptom control, and persistent impairments in daily functioning. The absence of reliable biomarkers, heterogeneous pathophysiology, and ongoing reliance on exclusionary diagnostic approaches contribute to shortcomings in care.

Join our expert faculty to review symptom-based diagnostic criteria, appropriate use of testing, current evidence-based treatment options, and practical strategies for individualized care. The program will also address communication approaches to promote shared decision-making and optimize long-term outcomes for patients with IBS.

Primary Care-Based Strategies for Improving IBS Care: Focus on Accurate Assessment and Personalized Treatment - Wednesday, February 18, 2026